Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 6
2019 6
2020 7
2021 8
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EM, Trawinska MM, Polverelli N, Tiribelli M, Benevolo G, Iurlo A, Tieghi A, Heidel FH, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Biondo M, Venturi M, Scaffidi L, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Bartoletti D, Paglia S, Vianelli N, Cavo M, Bonifacio M, Palumbo GA. Palandri F, et al. Among authors: bartoletti d. Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18. Cancer. 2023. PMID: 36932983 Free article.
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
Palandri F, Elli EM, Auteri G, Bonifacio M, Benevolo G, Heidel FH, Paglia S, Trawinska MM, Bosi C, Rossi E, Tiribelli M, Tieghi A, Iurlo A, Polverelli N, Caocci G, Binotto G, Cavazzini F, Beggiato E, Cilloni D, Tatarelli C, Mendicino F, Miglino M, Bocchia M, Crugnola M, Mazzoni C, Romagnoli AD, Rindone G, Ceglie S, D'Addio A, Santoni E, Cattaneo D, Bartoletti D, Lemoli RM, Krampera M, Cuneo A, Semenzato GC, Latagliata R, Abruzzese E, Vianelli N, Cavo M, Andriani A, De Stefano V, Palumbo GA, Breccia M. Palandri F, et al. Among authors: bartoletti d. Blood Cancer J. 2023 May 3;13(1):65. doi: 10.1038/s41408-023-00834-6. Blood Cancer J. 2023. PMID: 37137878 Free PMC article. No abstract available.
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Palandri F, Bartoletti D, Iurlo A, Bonifacio M, Abruzzese E, Caocci G, Elli EM, Auteri G, Tiribelli M, Polverelli N, Miglino M, Heidel FH, Tieghi A, Benevolo G, Beggiato E, Fava C, Cavazzini F, Pugliese N, Binotto G, Bosi C, Martino B, Crugnola M, Ottaviani E, Micucci G, Trawinska MM, Cuneo A, Bocchia M, Krampera M, Pane F, Lemoli RM, Cilloni D, Vianelli N, Cavo M, Palumbo GA, Breccia M. Palandri F, et al. Among authors: bartoletti d. Cancer. 2022 Jul 1;128(13):2449-2454. doi: 10.1002/cncr.34216. Epub 2022 Apr 1. Cancer. 2022. PMID: 35363892 Free PMC article.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, Palandri F. Polverelli N, et al. Among authors: bartoletti d. Br J Haematol. 2021 Apr;193(2):356-368. doi: 10.1111/bjh.17192. Epub 2020 Nov 21. Br J Haematol. 2021. PMID: 33222197 Free article.
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study.
Auteri G, Paglia S, Mazzoni C, Biondo M, Venturi M, Romagnoli AD, Bartoletti D, Cavo M, Vianelli N, Palandri F. Auteri G, et al. Among authors: bartoletti d. Mediterr J Hematol Infect Dis. 2023 May 1;15(1):e2023029. doi: 10.4084/MJHID.2023.029. eCollection 2023. Mediterr J Hematol Infect Dis. 2023. PMID: 37180204 Free PMC article.
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M, Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C, Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N, Cavo M, Breccia M, Bonifacio M. Palandri F, et al. Among authors: bartoletti d. Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1. Blood Cancer J. 2021. PMID: 33414394 Free PMC article. No abstract available.
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.
Palandri F, Rossi E, Bartoletti D, Ferretti A, Ruggeri M, Lucchini E, Carrai V, Barcellini W, Patriarca A, Rivolti E, Consoli U, Cantoni S, Oliva EN, Chiurazzi F, Caocci G, Giuffrida G, Borchiellini A, Auteri G, Baldacci E, Carli G, Nicolosi D, Sutto E, Carpenedo M, Cavo M, Mazzucconi MG, Zaja F, De Stefano V, Rodeghiero F, Vianelli N. Palandri F, et al. Among authors: bartoletti d. Blood. 2021 Aug 19;138(7):571-583. doi: 10.1182/blood.2021010735. Blood. 2021. PMID: 33889952 Free article. Clinical Trial.
28 results